Please	lyne	а	อเมร	sign	(+)	inside	this	צממ
10000	7,00	٠.	Since	A.3.C.	1.7	1110120		207.

PTO/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0651-0931
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	its for form 1449A/PTC)		Complete if Known			
* \$ \$ \$ \$ \$ \$ \$ \$	14 ~ 1*******	879.21	001 001100	Application Number	10/596,815		
			SCLOSURE	Filing Date	06-26-2006		
STATEMENT BY APPLICANT				First Named Inventor	SALTZMAN		
				Group Art Unit	1645		
	(use as many shed	ers a	s necessary)	Examiner Name	N. Archie		
Sheet	1	of	2	Attorney Docket Number	USAV2003/0020 - US - PCT		

***************************************	****************	***************************************		U.S. PATENT DOCL	IMENTS	***************************************
Examiner Initials	No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/N.A./		2003/224511		Kenneth	12-04-2003	
		ļ				
		ļ				

		····			-	***************************************
		·····				

		<u> </u>				·····
	******					·····

				FOR	EIGN PATENT DOCUMENT	rs	000000000000000000000000000000000000000	•
Examiner Initials	Cite No. ¹	Foreign Patent Document Kind Code ^s Office ^s Number ⁴ ((Fknown)		Kind Code ⁵ Name of Patentee of		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τs
/N.A	./	EP	1336847		Biofrontera Pharma	08-20-2003		
/N.A./		wo	02/055726		General Hospital Corp.	07-18-2002		\Box
/N.A./		wo	03/026403		Deltagen	04-03-2003		
					***************************************		***************************************	
					·····			
							***************************************	1
		ļ						
					parteer te est a ten a quantitat de entra la completa de entra completa de la completa de la completa de la co		and the contract contract of the contract of t	
		}		1				1 8

************************	\$0000000000000000000000000000000000000	{~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	/2000000000000000000000000000000000000
Examiner		Date	
Signature	/Nina Archie/	Considered	06/30/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Surden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please	type	a	olus	sion	{÷}	inside	this	box	_

PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1998, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substiti	ute for form 14498/	PTO		Complete if Known				
	en en a a mora e	~ * * * * * *	^^. ^^.	Application Number	10/596,815			
INT:	UKWATK	ונו אנ	SCLOSURE	Filing Date	06-26-2006			
STATEMENT BY APPLICANT				First Named Inventor	SALTZMAN			
				Group Art Unit	1646			
***	(use as man	ıy sheets i	as necessary)	Examiner Name	N. Archie			
Sheet	2	of	2	Attorney Docket Number	USAV2003/0020 - US - PCT			

and the second	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ?
Ý	GUNCAR et al., Crystal structur of cathepsin X: A flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease, Structure, Vol. 8, No. 3, March 15, 2000, pp. 305-313	
	KLEMENCIC et al., Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase, Eur. J. Biochem., Vol. 267, 2000, pp. 5404-5412	
	LENNON-DUMENIL et al., Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosomal proteolytic contents dring dendritic cell actiation, Journal of Experimental Medicine, Vol. 198, No.	·
	NAGLER et al., Human Cathepsin X: A Cysteine Protease With Unique Carboxypeptidase Activity, Biochemistry, Vol. 38, 1999, pp. 12648-12654	
****	NAGLER et al., Human cathepsin X: A novel cysteine protease of the papain family with a very short proregion and unique insertions, FEBS Letters, Vol. 434, 1998, pp. 135-139	
	RIESE et al., Cathepsins and compartmentalization in antigen presentation, Curr. Op. Immun, Vol. 12, 2000, pp. 107-113	
	SANTAMARIA et al., Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location, Journal of Biological Chemistry, Am. Soc. of Bio. Chemists, Vol. 273, No. 27, July 3, 1998, pp. 16816-16823	
	TROMBETTA et al., Activation of lysosomal function during dendritic cell maturation, Science, Vol. 299, No. 5611, Feb. 28, 2003, pp. 1400-1403	
	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. GUNCAR et al., Crystal structur of cathepsin X: A flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease, Structure, Vol. 8, No. 3, March 15, 2000, pp. 305-313 KLEMENCIC et al., Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase, Eur. J. Biochem., Vol. 267, 2000, pp. 5404-5412 LENNON-DUMENIL et al., Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosomal proteolytic contents dring dendritic cell actiation, Journal of Experimental Medicine, Vol. 198, No. 4, Aug. 19, 2002, pp. 529-539 NAGLER et al., Human Cathepsin X: A Cysteine Protease With Unique Carboxypeptidase Activity, Biochemistry, Vol. 38, 1999, pp. 12648-12654 NAGLER et al., Human cathepsin X: A novel cysteine protease of the papain family with a very short proregion and unique insentions, FEBS Letters, Vol. 434, 1998, pp. 135-139 RIESE et al., Cathepsins and compartmentalization in antigen presentation, Curr. Op. Immun, Vol. 12, 2000, pp. 107-113 SANTAMARIA et al., Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location, Journal of Biological Chemistry, Am. Soc. of Bio. Chemists, Vol. 273, No. 27, July 3, 1998, pp. 16816-16823

	CONTRACTOR DESCRIPTION OF THE PROPERTY OF THE		000000000000000000000000000000000000000	becommencement and a second	
9	Examiner		Date	00/00/0000	
-	Signature	/Nina Archie/	Considered	06/30/2008	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.